| Investigator, Principal |
| Completed | 4 | 144 | Europe | Opicapone 50 mg, BIA 9-1067, Placebo | Bial - Portela C S.A., Bial - Portela & Ca, S.A. | Parkinson Disease | 02/24 | 02/24 | | |
NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy |
|
|
| Recruiting | 4 | 100 | US | Ketamine | University of Oklahoma | Hemorrhoids | 01/25 | 07/25 | | |
NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease |
|
|
| Completed | 4 | 140 | RoW | Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox | Daiichi Sankyo | COPD Exacerbation Acute | 09/24 | 09/24 | | |
TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, With Loperamide Adjunct |
|
|
| Recruiting | 4 | 150 | RoW | Rifaximin 550 MG, Azithromycin 500 MG, Loperamide | Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences | Diarrhoea;Acute, Diarrhea Travelers | 09/25 | 12/25 | | |
NefXtend, NCT06712407: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy |
|
|
| Recruiting | 4 | 60 | US | TARPEYO®, delayed-release budesonide capsules | Calliditas Therapeutics AB, Worldwide Clinical Trials | IgA Nephropathy | 05/26 | 11/27 | | |
CLEAR Taiwan, NCT06925100: A Study to Investigate the Effectiveness and Safety of Bempedoic Acid in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia in Taiwan |
|
|
| Completed | 4 | 180 | RoW | Bempedoic acid 180 mg tablet | Daiichi Sankyo | Primary Hypercholesterolemia or Mixed Hyperlipidemia | 10/25 | 10/25 | | |
POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin |
|
|
| Terminated | 4 | 109 | US | Tamsulosin Hydrochloride | University of Massachusetts, Worcester, UMass Memorial Health Care | Thoracic Diseases, Urinary Retention | 10/23 | 10/23 | | |
NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction |
|
|
| Recruiting | 4 | 40 | US | fentanyl and Remimazolam | Indiana University, Indiana University Health | Dental Extraction | 03/26 | 03/26 | | |
| Not yet recruiting | 4 | 50 | US | Trimethoprim-Sulfamethoxazole (TMP-SMX), Usual Care | University of California, San Francisco | Kidney Transplant, Urinary Tract Infection(UTI), Antibiotic Prophylaxis, Remote Patient Monitoring, Feasibility Pilot Study | 12/28 | 01/29 | | |
NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients |
|
|
| Not yet recruiting | 4 | 100 | US | Skin Cleanser Combination No.1 | Boston Children's Hospital | Atopic Dermatitis | 12/35 | 12/39 | | |
NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) |
|
|
| Completed | 3 | 165 | Europe, Canada, US, RoW | Macitentan, ACT-064992, Standard-of-care | Actelion | Pulmonary Arterial Hypertension | 08/24 | 11/25 | | |
| Active, not recruiting | 3 | 605 | Europe, Canada, Japan, US, RoW | DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel | Daiichi Sankyo, AstraZeneca | Non-small Cell Lung Cancer | 05/24 | 01/26 | | |
|
|
|
|
IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 540 | Europe, Canada, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Small Cell Lung Cancer | 04/27 | 02/29 | | |
TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC |
|
|
| Not yet recruiting | 3 | 632 | RoW | docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy | Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 06/24 | 06/26 | | |
| Completed | 3 | 55 | Europe, Japan, US | Chronocort, Hydrocortisone modified-release, Cortef, Immediate-release hydrocortisone, IRHC, Placebo | Neurocrine UK Limited, Diurnal Limited | Congenital Adrenal Hyperplasia | 02/24 | 02/24 | | |
NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location |
|
|
| Recruiting | 3 | 50 | US | Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol | Planned Parenthood League of Massachusetts | Abortion | 07/24 | 09/24 | | |
| Active, not recruiting | 3 | 586 | Europe, Canada, Japan, US, RoW | Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy | Daiichi Sankyo, Merck Sharp & Dohme LLC | Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion | 05/24 | 06/26 | | |
CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy |
|
|
| Active, not recruiting | 3 | 102 | Europe, Canada, US, RoW | Ampreloxetine, TD-9855, Placebo | Theravance Biopharma | Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy | 01/26 | 01/28 | | |
NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential |
|
|
| Recruiting | 3 | 1500 | US | Transdermal system containing progestin | Mylan Pharmaceuticals Inc | Female Contraception | 03/27 | 04/27 | | |
LIBERTY, NCT06716814: Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa |
|
|
| Recruiting | 3 | 104 | Europe | Efanesoctocog alfa, BIVV001, Altuvoct, Altuviiio, Recombinant coagulation factor VIII Fc-von-Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN) | Swedish Orphan Biovitrum, PSI CRO | Severe Haemophilia A | 03/27 | 03/27 | | |
| Recruiting | 3 | 869 | Canada, US | Plozasiran Injection, ARO-APOC3 | Arrowhead Pharmaceuticals | Hypertriglyceridemia | 07/28 | 07/28 | | |
| Enrolling by invitation | 3 | 615 | RoW | Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection | Beijing VDJBio Co., LTD. | Rheumatoid Arthritis (RA), Anti IL-6R | 04/26 | 12/26 | | |
| Active, not recruiting | 3 | 899 | Europe, Canada, Japan, US, RoW | Tafasitamab, Monjuvi, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo | Incyte Corporation | Diffuse Large B-cell Lymphoma | 09/26 | 11/27 | | |
|
|
|
| Completed | 3 | 1 | US | StrataGraft | Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority | Skin Wound, Burns, Trauma-related Wound | 05/24 | 05/24 | | |
NCT06973629: Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY) |
|
|
| Not yet recruiting | 3 | 200 | US | Debamestrocel - MSC-NTF (NurOwn), NurOwn, Placebo | Brainstorm-Cell Therapeutics | Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis | 11/28 | 05/29 | | |
| Active, not recruiting | 3 | 490 | Europe, Japan, RoW | Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel | Daiichi Sankyo, AstraZeneca | Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 08/26 | 08/26 | | |
|
|
|
|
|
IPAX BrIGHT, NCT07100730: Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma |
|
|
| Recruiting | 3 | 50 | RoW | TLX-101-Tx + Lomustine, 131I-IPA, 131I-TLX101, TLX101-Tx | Telix Pharmaceuticals (Innovations) Pty Limited | Neoplastic Disease, Glioblastoma, Glioblastoma (GBM), Glioblastoma Multiform, Glioblastoma Multiforme, Adult, Glioblastoma Multiforme (GBM) WHO Grade IV | 07/27 | 11/27 | | |
| Recruiting | 3 | 500 | US | daraxonrasib | Revolution Medicines, Inc. | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC), Resected Pancreatic Adenocarcinoma | 05/29 | 07/30 | | |
NCT05847348: 68Ga-PSMA-11 Efficacy in Detecting BCR Prostate Cancer in Chinese Patients |
|
|
| Recruiting | 3 | 110 | RoW | 68Ga-PSMA-11, Illucix, gallium Ga 68 Gozetotide, PET/CT or PET/MRI, Imaging by PET | Telix Pharmaceuticals (Innovations) Pty Limited, Grand Pharmaceutical (China) Co., Ltd. | Biochemical Recurrence of Malignant Neoplasm of Prostate, Prostate Cancer, BCR Prostate Carcinoma | 12/25 | 07/26 | | |
EVER, NCT05037279: Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) |
|
|
| Recruiting | 3 | 540 | Canada | Bacillus Calmette-Guerin: Strain Russian BCG-I, Verity-BCG, Bacillus Calmette-Guerin: Strain TICE, OncoTICE | Verity Pharmaceuticals Inc. | Bladder Cancer, Bladder Cancer Recurrent, Neoplasm Recurrence, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Non-Invasive Bladder Urothelial Carcinoma | 02/29 | 02/29 | | |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, GBG Forschungs GmbH, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
|
FREEDOM, NCT05817812: A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa |
|
|
| Active, not recruiting | 3 | 93 | Europe, RoW | Efanesoctocog alfa, BIVV001 | Swedish Orphan Biovitrum, Syneos Health | Hemophilia A, Severe | 05/26 | 06/26 | | |
TROPION-Lung07, NCT05555732: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 3 | 1170 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA®, Pemetrexed, Alimta, Pemfexy, Carboplatin, Cisplatin | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 08/27 | 08/27 | | |
DESTINY-Breast15, NCT05950945: Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 250 | Europe, US, RoW | Trastuzumab Deruxtecan, T-DXd, DS-8201a (trastuzumab derextecan), Enhertu® | Daiichi Sankyo, AstraZeneca | Breast Cancer | 10/27 | 10/27 | | |
| Recruiting | 3 | 740 | Europe, Canada, Japan, US, RoW | Datopotamab Deruxtecan, Dato-DXd, Pembrolizumab, KEYTRUDA® | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Metastatic Non Small Cell Lung Cancer | 02/28 | 04/28 | | |
|
|
ARTEMIS, NCT04797884: Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2/3 | 166 | US | TheraBionic Device, Placebo Device, Quality of Life Assessment | THERABIONIC INC., National Cancer Institute (NCI) | Hepatocellular Carcinoma | 10/24 | 10/24 | | |
FORTIFI-HN01, NCT06788990: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC |
|
|
| Recruiting | 2/3 | 650 | Europe, Canada, US, RoW | Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo | Bicara Therapeutics | Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | 04/28 | 07/29 | | |
NCT06873334: Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease |
|
|
| Recruiting | 2/3 | 120 | RoW | SKY-0515, SKY-0515 Placebo | Skyhawk Therapeutics, Inc. | Huntington Disease, Huntingtons Disease | 05/27 | 12/27 | | |
NCT06947499: A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series |
|
|
| Recruiting | 2/3 | 1186 | RoW | LBVD, Pentavalent vaccine and Inactivated Polio vaccine | LG Chem | Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis, Haemophilus Influenzae Type b | 11/26 | 04/27 | | |
TRIPHASE, NCT06101745: Trial to Visualize the Ureters With Nizaracianine Triflutate in Adults Undergoing Abdominopelvic Surgery |
|
|
| Recruiting | 2/3 | 336 | Europe, US | Nizaracianine Triflutate, ZW800-1, Placebo Comparator, Sugar | Curadel Surgical Innovations, Inc., Leiden University Medical Center, Erasmus Medical Center, University of Massachusetts Chan Medical School, Worcester, Stanford University, Cedars-Sinai Medical Center, University Medical Center Groningen, Martini Hospital Groningen, Isala | Injury of Ureter During Surgery (Disorder) | 02/26 | 03/26 | | |
| Terminated | 2 | 16 | Europe, Canada, US, RoW | Belcesiran, Placebo | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | Alpha 1-Antitrypsin Deficiency | 12/23 | 05/24 | | |
AAVIATE, NCT04514653: RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
|
|
| Recruiting | 2 | 140 | US | Ranibizumab, ABBV-RGX-314 Dose 1, Combination Product, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Local Steroid, Topical Steroid, ABBV-RGX-314 Dose 4 | AbbVie, REGENXBIO Inc. | Neovascular Age-Related Macular Degeneration (nAMD) | 08/26 | 02/27 | | |
| Completed | 2 | 60 | US | RGX-314 | AbbVie | Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration | 10/23 | 03/24 | | |
Orchid 1, NCT06132919: Efficacy and Safety of MC2-25 Cream & Vehicle in Women With Vulvar Lichen Sclerosus (VLS) |
|
|
| Completed | 2 | 33 | Europe | MC2-25 cream, MC2-25 vehicle | MC2 Therapeutics | Vulvar Lichen Sclerosus | 11/24 | 11/24 | | |
| Recruiting | 2 | 740 | Europe, Canada, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer | 09/27 | 10/28 | | |
NCT05198310 / 2022-000169-42: Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor |
|
|
| Completed | 2 | 145 | Europe, US, RoW | KPL-404, abiprubart, Placebo | Kiniksa Pharmaceuticals, Ltd., Kiniksa Pharmaceuticals, Ltd. | Arthritis, Rheumatoid | 02/24 | 05/24 | | |
| Recruiting | 2 | 90 | US | Hydroxypropyl Beta Cyclodextrin, Trappsol Cyclo, Placebo, 0.5N saline | Cyclo Therapeutics, Inc., Cyclo Therapeutics Inc. | Alzheimer's Disease | 03/24 | 03/24 | | |
| Completed | 2 | 65 | Europe, US | DS-1211b, Placebo | Daiichi Sankyo, PXE International | Pseudoxanthoma Elasticum | 11/23 | 11/23 | | |
IDeate-PanTumor02, NCT06330064: A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors |
|
|
| Recruiting | 2 | 520 | Europe, Japan, US, RoW | Ifinatamab deruxtecan, I-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Recurrent or Metastatic Solid Tumors | 07/28 | 07/28 | | |
NCT04870905: Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Not yet recruiting | 2 | 100 | RoW | Tis-U-Sol | Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Union hospital of Fujian Medical University, Zhujiang Hospital, Guangdong Provincial People's Hospital | Nasopharyngeal Neoplasms | 05/24 | 05/26 | | |
MAST, NCT06355583: Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant () Trial |
|
|
| Recruiting | 2 | 50 | Europe | EBX-102, IMT capsules, Placebo | Imperial College London | Acute Lymphoblastic Leukaemia, Acute Leukemia of Ambiguous Lineage, Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia | 02/26 | 05/27 | | |
NCT07282262: An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy. |
|
|
| Recruiting | 2 | 300 | RoW | Ivosidenib, Lenvatinib, PD-1/PD-L1 inhibitor | Peking Union Medical College Hospital | Biliary Tract Cancer | 10/26 | 10/26 | | |
| Active, not recruiting | 2 | 187 | Europe, Japan, US, RoW | Ifinatamab Deruxtecan (I-DXd), DS-7300a | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive-stage Small-cell Lung Cancer | 03/25 | 12/26 | | |
|
| Active, not recruiting | 2 | 32 | US, RoW | SPG302, Placebo | Spinogenix | Schizophrenia | 03/26 | 03/26 | | |
CBeyond, NCT06577090: Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo |
|
|
| Active, not recruiting | 2 | 136 | US | Nimacimab injection, Nimacimab placebo injection, semaglutide injection, Nimacimab 300 mg injection | Skye Bioscience, Inc., Bird Rock Bio Sub, Inc. | Obesity | 11/26 | 02/27 | | |
NCT05029336: Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases |
|
|
| Recruiting | 2 | 20 | US | Depletion of CD3/CD19 in an autologous stem cell transplant, CD3/CD19 depletion using cliniMACs device | Stephan Grupp MD PhD | Systemic Lupus Erythematosus, Systemic Sclerosis | 12/27 | 05/31 | | |
| Recruiting | 2 | 64 | US | Bevonescein, ALM-488 | Alume Biosciences, Inc. | Surgery, Nerve Injury, Imaging | 06/25 | 09/25 | | |
| Recruiting | 2 | 230 | Europe, Canada, US, RoW | TORL-1-23, Pegfilgrastim (drug) | TORL Biotherapeutics, LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT) | Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer | 10/27 | 12/27 | | |
NCT04935762: A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012) |
|
|
| Withdrawn | 2 | 25 | RoW | CST-103, CST-107, matching placebo | CuraSen Therapeutics, Inc. | Freezing of Gait Symptoms in Parkinson's Disease | 12/24 | 03/25 | | |
| Recruiting | 2 | 200 | Europe, Japan, US, RoW | Raludotatug deruxtecan, R-DXd | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Metastatic Solid Tumors | 09/27 | 09/27 | | |
NCT06833749: Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis |
|
|
| Recruiting | 2 | 600 | Europe, RoW | KBP-336, Placebo | KeyBioscience AG | Osteoarthritis in the Knee, Obesity | 11/26 | 12/26 | | |
NCT06830629: A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease |
|
|
| Recruiting | 2 | 56 | Europe, US | MZE829 | Maze Therapeutics | Proteinuric Kidney Disease | 09/26 | 09/26 | | |
NCT06843239: Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) |
|
|
| Recruiting | 2 | 80 | Europe, US, RoW | Tibulizumab, ZB-106, Placebo, ZB-106 placebo | Zura Bio Inc | Systemic Sclerosis (SSc), Scleroderma | 05/27 | 01/28 | | |
NCT04977024: SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer |
|
|
| Active, not recruiting | 2 | 63 | US | COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1, COH04S1, SARS-CoV-2 Vaccine COH04S1, sMVA-based SARS-CoV-2 Vaccine COH04S1, GEO-CM04S1 | GeoVax, Inc., National Cancer Institute (NCI) | COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma | 12/26 | 12/27 | | |
| Recruiting | 2 | 225 | Europe, Canada, US | Tibulizumab Dose A, Tibulizumab Dose B, Placebo | Zura Bio Inc | Hidradenitis Suppurativa (HS) | 11/26 | 04/27 | | |
ULTRAMARINE, NCT07080034: Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis |
|
|
| Recruiting | 2 | 198 | RoW | anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, high dose, Placebo | Biocad | Ulcerative Colitis (UC) | 01/27 | 10/28 | | |
COMANDOR, NCT07078994: Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease |
|
|
| Recruiting | 2 | 204 | RoW | anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, high dose, Placebo | Biocad | Crohn's Disease (CD) | 05/27 | 01/29 | | |
NCT06868485: A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 40 | Europe, US, RoW | WSD0922-FU Tablets, Dose level A, WSD0922, WSD0922-FU Tablets, Dose level B | Wayshine Biopharm, Inc. | Non Small Cell Lung Cancer | 09/27 | 12/27 | | |
NCT06867107: A Long-term Follow-up Study for Participants That Completed the SAT-3247-CL-101 Study |
|
|
| Enrolling by invitation | 2 | 10 | RoW | SAT-3247 | Satellos Bioscience, Inc. | Duchenne Muscular Dystrophy (DMD) | 08/26 | 08/26 | | |
NCT07191483: A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia |
|
|
| Recruiting | 2 | 150 | US | KYN-5356 low dose, Placebo, KYN-5356 Medium Dose, KYN-5356 High Dose | Kynexis B.V. | Cognitive Impairment Associated With Schizophrenia (CIAS) | 10/25 | 12/26 | | |
NCT06038578: A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer |
|
|
| Recruiting | 2 | 146 | Japan, US, RoW | TRK-950, Ramucirumab, CYRAMZA®, Paclitaxel | Toray Industries, Inc | Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 06/26 | 06/26 | | |
NCT07089043: A Study in Subjects With Neurogenic Orthostatic Hypotension |
|
|
| Recruiting | 2 | 12 | US | CST-3056, Placebo | CuraSen Therapeutics, Inc. | Neurogenic Orthostatic Hypotension | 01/26 | 02/26 | | |
| Recruiting | 2 | 120 | Canada, US | COYA 302, LD rhIL-2 and CTLA-4 Ig, Placebo | Coya Therapeutics | Amyotrophic Lateral Sclerosis (ALS) | 01/27 | 07/27 | | |
STEP, NCT06594393: A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, -study |
|
|
| Recruiting | 2 | 32 | Europe | TCP-25 gel, Vehicle (placebo) | Xinnate AB | Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa | 06/27 | 06/27 | | |
| Not yet recruiting | 2 | 320 | US | High THC Cannabis, Placebo cannabis | Multidisciplinary Association for Psychedelic Studies, Changemark Research + Evaluation Ltd. | Post Traumatic Stress Disorder PTSD | 06/27 | 11/27 | | |
NCT05205330 / 2020-002435-29: Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers |
|
|
| Active, not recruiting | 1/2 | 107 | Europe | CR6086, vorbipiprant, AGEN2034, balstilimab | Rottapharm Biotech, Agenus Inc. | Refractory Metastatic Colorectal Cancer, Solid Tumor, Metastatic Microsatellite-stable Colorectal Cancer, Mismatch Repair Protein Proficient, Metastatic GI Cancers, Gastric Cancer | 12/26 | 06/27 | | |
NCT05423262: A Study of TRK-950 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 49 | Japan | TRK-950, Nivolumab | Toray Industries, Inc | Solid Tumor, Melanoma | 12/27 | 12/27 | | |
| Terminated | 1/2 | 13 | US | AG Tx, Meshed Autograft, SOMA Tx, StrataGraft skin tissue Overlay of Meshed Autograft (SOMA) | Stratatech, a Mallinckrodt Company | Full Thickness Thermal Burn | 06/24 | 06/24 | | |
NCT05638802: A Study of DS-7011a in Patients With Systemic Lupus Erythematosus |
|
|
| Completed | 1/2 | 26 | US | DS-7011a, Placebo | Daiichi Sankyo | Systemic Lupus Erythematosus | 04/25 | 04/25 | | |
| Completed | 1/2 | 192 | Europe, US | ASTX029 | Taiho Oncology, Inc. | Solid Tumor, Adult | 08/24 | 03/25 | | |
NCT05979831: A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome |
|
|
| Active, not recruiting | 1/2 | 9 | Europe | DS-2325a, Placebo | Daiichi Sankyo | Netherton Syndrome | 01/25 | 01/25 | | |
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 123 | Europe, Japan, US | Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Extensive Stage-small Cell Lung Cancer | 09/26 | 12/26 | | |
| Terminated | 1/2 | 53 | US, RoW | SQ3370 | Shasqi, Inc. | Cancer | 09/23 | 09/23 | | |
WSD0922-102, NCT06631989: A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 100 | RoW | WSD0922-FU, WSD0922 | Wayshine Biopharm, Inc. | EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer | 06/27 | 12/27 | | |
| Recruiting | 1/2 | 160 | Europe, RoW | Bevacizumab, Dinutuximab beta, Irinotecan (drug), Topotecan, Temozolomide (TMZ) | University of Birmingham | Relapsed Neuroblastoma | 12/30 | 12/30 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 04/27 | 10/29 | | |
|
| Active, not recruiting | 1/2 | 666 | Europe, Canada, US, RoW | Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™ | Genmab, AbbVie | DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL, MCL, Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma (MZL), Indolent B-cell Non-Hodgkin Lymphoma (iNHL), Aggressive B-cell Non-Hodgkin Lymphoma (aNHL) | 01/29 | 01/29 | | |
|
|
|
|
|
|
|
|
|
|
|
NCT06874621: VY7523-102: Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in Participants With Early Alzheimer's Disease |
|
|
| Active, not recruiting | 1/2 | 52 | Canada, US | VY7523, Placebo Comparator | Voyager Therapeutics | Alzheimer's Disease (AD) | 05/27 | 05/27 | | |
| Recruiting | 1/2 | 42 | US | RXRG001, Placebo | RiboX Therapeutics Ltd. | Radiation-Induced Xerostomia and Hyposalivation | 08/27 | 08/27 | | |
NCT05693025: Evaluation of the Walk With Ease Program for Fall Prevention |
|
|
| Recruiting | 1/2 | 240 | US | Group Exercise, Behavioral Training | Iowa State University | Exercise, Frailty, Arthritis, Accidental Falls | 05/25 | 05/26 | | |
NCT07169734: A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors |
|
|
| Recruiting | 1/2 | 180 | US, RoW | ALE.P03 | Alentis Therapeutics AG | Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma | 04/29 | 10/29 | | |
TORL123-004, NCT07322094: CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer |
|
|
| Recruiting | 1/2 | 60 | US | TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin | TORL Biotherapeutics, LLC | FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer | 12/27 | 01/28 | | |
NCT07220616: A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies |
|
|
| Recruiting | 1/2 | 420 | Japan | DS3790a, Combination drug | Daiichi Sankyo | Hematological Malignancies | 11/30 | 11/30 | | |
| Recruiting | 1/2 | 540 | Europe, Canada, Japan, US, RoW | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 02/27 | | |
NCT03793478 / 2016-002919-18: Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood |
|
|
| Active, not recruiting | 1/2 | 65 | Europe, Canada, US, RoW | Quizartinib, Quizartinib dihydrochloride, Vanflyta, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide | Daiichi Sankyo, Innovative Therapies For Children with Cancer Consortium, Children's Oncology Group | Acute Myeloid Leukemia | 05/27 | 05/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT05203692: A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects |
|
|
| Completed | 1 | 80 | US | DS-7011a, Placebo | Daiichi Sankyo, Inc. | Systemic Lupus Erythematosus | 01/23 | 03/23 | | |
NCT05388903: A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects |
|
|
| Completed | 1 | 64 | US | DS-2325a, Placebo | Daiichi Sankyo, Inc. | Netherton Syndrome | 01/23 | 01/23 | | |
NCT05484414: Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA) |
|
|
| Not yet recruiting | 1 | 56 | US | SRP-3D (diethylamide), SRP-3D (DA), Placebo, Control | South Rampart Pharma, LLC | Pain | 12/25 | 03/26 | | |
NCT05844202: Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention |
|
|
| Completed | 1 | 130 | RoW | Alveavax-v1.2, Alveavax, Janssen Ad26.COV2.S, Janssen | Alvea Holdings, LLC | Sars-CoV-2 Infection | 03/23 | 03/23 | | |
